Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016321 · ClinicalTrials.gov registry record · Phase 2
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
A Phase 2 study, sponsored by Johns Hopkins University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT07016321: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT07016321 is a Phase 2 study that has not yet begun recruiting, run by Johns Hopkins University. The registered enrollment target is 600 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07016321, a Phase 2 study, has not yet begun recruiting, sponsored by Johns Hopkins University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)? 2. What are the safety outcomes of emetine, including serious adverse events and toxicities? Participants will be asked to: 1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen. 2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters. 3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.
Primary Outcome
28-day mortality or progression to severe dengue, defined as severe plasma leakage, severe bleeding, or severe organ involvement (death and severe dengue will be assessed as a composite outcome)
Interventions
- DRUG Placebo
- DRUG Emetine Hydrochloride 6mg
- DRUG Emetine Hydrochloride 12mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-06-25 |
| Est. Completion | 2029-05-03 |
| Phase | Phase 2 |
What is known before NCT07016321 opens enrollment
NCT07016321 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07016321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07016321 about?
NCT07016321 is a clinical study titled "Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)". The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma lea...
What is the current status of trial NCT07016321?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2026-06-25. Estimated completion is 2029-05-03.
What interventions are being tested in trial NCT07016321?
The interventions under investigation include: Placebo (DRUG), Emetine Hydrochloride 6mg (DRUG), Emetine Hydrochloride 12mg (DRUG).
Who is sponsoring clinical trial NCT07016321?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07016321's enrollment target sits among peer trials
600 53rd of 2000 higher than 1,945 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI